Best China Stocks To Own For 2018

As the year comes to a close, it’s fitting that the week in solar was dominated by the kind of large, macro trends that seem to move and shake the solar industry every few months. But unlike 2015, when we had Nevada upend net metering in the final hours of the year, most of the news from the solar industry is positive at the end of 2016. There are still some challenges looking forward, but policy seems to be favoring solar energy in the long term.

Image source: Getty Images.

China resets renewable energy prices

One of the biggest drivers of solar growth in 2016 was China’s feed-in tariff rates. A feed-in tariff drove an estimated 13 GW of solar installations in the first half of the year before being reset in the second half. Now feed-in tariff rates will fall another 19% for 2017, and China has lowered its 2020 installation target from 150 GW to a minimum of 105 GW.

Best China Stocks To Own For 2018: Denison Mine Corp(DNN)

Advisors’ Opinion:

  • [By Jim Robertson]

    Last Thursday, small cap uranium mining stock Denison Mines Corp (NYSEAMERICAN: DNN), which is alsofocused on the Athabasca Basin of Saskatchewan, reported 2017 earnings and gave its outlook for 2018 with the outlook coming with extensive commentary about the uranium market and Athabasca. David Cates, the President and CEO of Denison Mines Corp,gave the following commentary:

Best China Stocks To Own For 2018: Ascent Capital Group, Inc.(ASCMA)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Ascent Capital Group (ASCMA)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Shane Hupp]

    Ascent Capital Group (NASDAQ: ASCMA) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap industrial products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Best China Stocks To Own For 2018: Horizon Global Corporation(HZN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Horizon Global (NYSE:HZN) has earned an average rating of “Hold” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $15.08.

  • [By Lisa Levin]


    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

  • [By Brian Feroldi]

    Horizon Global(NYSE:HZN)reported its first-quarter results on May 3. The provider ofbranded towing and trailering equipment had already warned investors that it was going through tough times but promised that it would take action to fix its problems.Let’s dig into the company’s results to see if those actions are starting to pay off.